| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 11 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2022 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $12.94 | $3,235.00 | - | +2.2% | -15.3% | |
| Dec 9, 2022 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $13.11 | $26,220.00 | - | -0.6% | -9.2% | |
| Dec 2, 2022 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $13.84 | $13,840.00 | - | +6.5% | -15.0% | |
| Dec 2, 2022 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 250 | $13.98 | $3,495.00 | - | +6.5% | -15.0% | |
| Nov 2, 2022 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $8.79 | $17,580.00 | - | +125.2% | -1.9% | |
| Oct 14, 2022 | Patel Snehal61 | CEO And CFO | Buy | 3,000 | $9.75 | $29,250.00 | +0.1% | +64.7% | -12.4% | |
| Oct 7, 2022 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $9.72 | $19,440.00 | - | +46.9% | -7.7% | |
| Sep 30, 2022 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $9.46 | $9,460.00 | - | +67.8% | -2.9% | |
| Sep 29, 2022 | Patel Snehal61 | CEO And CFO | Buy | 1,000 | $9.23 | $9,230.00 | - | +78.2% | -6.7% | |
| Jun 24, 2022 | Patel Snehal61 | CEO And CFO | Buy | 29,000 | $9.13 | $264,770.00 | +0.5% | +8.5% | +13.8% |